The Eurocare-5 study, a population-based registry study of cancer survival across Europe, has found significant improvements in the five-year survival rates for haematological malignancies between 1997 and 2008. The results, published online in the Lancet Oncology, showed for example that amongst myeloma patients the five-year survival rate increased from 29.8% to 39.6%. These gains coincided with the introduction of more effective treatments although some regions showed better outcomes than others. The authors indicated that collection of further data at diagnosis and various disease stages could provide more evidence of treatment effectiveness and help explain the geographical variations that exist.

Read the full article